- 作者：Jens M. Kittner ; Nora M. Weiss ; J枚rg Wiltink ; J枚rg M. Schattenberg ; Annette Grambihler ; Florian Thieringer ; Arndt Weinmann ; Tim Zimmermann ; S ; ra Koch ; Marcus Schuchmann ; Peter R. Galle
- 关键词：Boceprevir ; Chronic hepatitis C genotype 1 ; DAAs ; Telaprevir ; Therapy decision ; Real-life data
- 刊名：Digestive and Liver Disease
- 出版年：January, 2014
- 年：2014
- 卷：46
- 期：1
- 页码：67-71
- 全文大小：185 K
Background
In chronic genotype 1 hepatitis C, telaprevir or boceprevir plus peginterferon and ribavirin have become the new standard of care. Aim of this study was to identify factors contributing to the decision whether to defer or treat with the current triple regimens.Methods
Prospective assessment of eight parameters on 0-4-point scales by the attending physician at a German tertiary referral centre between 1st September 2011 and 31st December 2012.
Results
307 patients were evaluated at least once by one of the 11 hepatologists involved; 267 patients were considered, but only 163 were recommended to receive triple therapy. Multivariate regression analysis revealed that a higher degree of fibrosis was most strongly associated with a recommendation for treatment (OR 2.69), followed by the patients鈥?demand (OR 2.27), presumed efficacy (OR 1.62), and tolerability (OR 1.58). A high risk of decompensation was associated with the decision to defer (OR 0.39). Speed of progression, compliance, extrahepatic manifestation, gender and age were not significantly related to the recommendation. Treatment was finally started in 101 patients (32.9%).
Conclusion
In chronic genotype 1 hepatitis C, advanced fibrosis and patients鈥?preference are the main rationales to choose treatment rather than deferral in a real-life setting.